CANY
RYTM icon

Caxton Associates (New York)’s Rhythm Pharmaceuticals RYTM Stock Holding History

Caxton Associates (New York)’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,491
Closed -$602K – 651
2024
Q3 		$602K Buy
+11,491
New +$551K 0.02% 338
2022
Q3 		– Sell
-151,213
Closed -$628K – 645
2022
Q2 		$628K Buy
151,213
+110,105
+268% +$603K 0.06% 218
2022
Q1 		$474K Sell
41,108
-18,289
-31% -$161K 0.04% 265
2021
Q4 		$593K Buy
+59,397
New +$667K 0.06% 230

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caxton Associates (New York)'s RYTM Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2024, closing a stake of 11,491 shares — an estimated $602K sold.

Caxton Associates (New York) first reported a position in RYTM in Q4 2021 and held it in 4 quarters. The position peaked at $628K in Q2 2022. 203 funds tracked by Wall St. Rank hold RYTM as of Q4 2024.

  • Caxton Associates (New York) reported no remaining Rhythm Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 11,491 Rhythm Pharmaceuticals shares in Q4 2024, an estimated $602K.
  • Caxton Associates (New York) first reported a position in Rhythm Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Caxton Associates (New York)'s Rhythm Pharmaceuticals position peaked at $628K in Q2 2022.
  • 203 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.